The China Compounding Pharmacy Market was valued at $340.1 Million in 2025 and projected to reach to $469.5 Million by 2030, representing a compound annual growth rate of 6.7%. China's compounding pharmacy market is positioned for sustained growth through 2030, driven by demographic shifts and healthcare modernization.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China's compounding pharmacy market is valued at USD 340.1 million in 2025, with a robust CAGR of 6.7%, significantly outpacing the global growth rate of 5.7%, demonstrating strong regional momentum.
China's rapidly aging demographic, combined with rising prevalence of chronic diseases such as diabetes and hypertension, is fueling demand for personalized medication solutions tailored to individual patient needs.
Chinese regulatory authorities are increasingly supportive of pharmaceutical customization and compounding practices, creating a favorable environment for market expansion and innovation in personalized medicine.
The market is projected to reach USD 469.5 million by 2030, representing a 38% increase over five years, reflecting sustained demand for customized pharmaceutical solutions across China's healthcare system.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides sterile and non-sterile compounding services, including ready-to-dispense and ready-to-administer personalized medicines for pharmacies, hospitals, and clinics | Its compounding operations support customized strengths, dosage forms, ingredient requirements, and therapies where commercially available medicines may be unsuitable or unavailable. | Enables healthcare providers to address patient-specific medication requirements, drug shortages, discontinued products, allergies, and dosage-form limitations while outsourcing complex sterile and non-sterile compounding activities. |
|
|
Operates both a 503A compounding pharmacy for patient-specific prescriptions and an FDA-registered 503B outsourcing facility for office-use medications | Its portfolio includes compounded preparations across multiple therapeutic areas and dosage forms, supported by sterile batch testing and cGMP processes at the 503B facility. | Expands access to individualized medicines and multiple strengths and dosage forms while enabling healthcare providers to procure larger-scale compounded products from a regulated outsourcing facility. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HORMONE REPLACEMENT THERAPIES (Therapeutic Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.7% from 2025 to 2030 |
| Largest Segment | PHARMACEUTICAL DOSAGE ALTERATION (Compounding Type) |
| Market Size Base Year (Billions) | ~USD 14.71 (2025) |
| Revenue Forecast (Billions) | ~USD 19.41 (2030) |
| Segments Covered | Product, Compounding Type, Therapeutic Application |
3 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ADULTS | 468.6 | 526.6 | 579.5 | 627.1 | 669.2 | 707.3 | 748.2 | 794.1 | 6.5 |
| GERIATRIC PATIENTS | 209.3 | 233.5 | 255.2 | 274.2 | 290.5 | 304.9 | 320.2 | 337.3 | 5.7 |
| PEDIATRIC PATIENTS | 136.4 | 155.7 | 174 | 191.2 | 207.1 | 222.2 | 238.5 | 256.8 | 8.1 |
| TOTAL | 814.3 | 915.8 | 1008.6 | 1092.6 | 1166.8 | 1234.4 | 1307 | 1388.3 | 6.6 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BAXTER | United States | Public Company | Medical Products & Therapies (IV, infusion, parenteral nutrition, renal-related therapies),Healthcare Systems & Technologies (smart beds, monitoring, OR integration, surgical equipment),Pharmaceuticals (generic and specialty injectables, inhaled anesthetics, compounding services), |
| FAGRON | Belgium | Public Company | Essentials (APIs, excipients, bases),Brands (derma, immunology, hair, scar care),Compounding Services, |
Baxter is a publicly traded American healthcare company founded in 1931 that employs 37,500 people. The company operates as a major medical device and pharmaceutical manufacturer serving global markets.
Fagron is a publicly traded Belgian pharmaceutical company founded in 1990 with 4,880 employees. The company focuses on pharmaceutical compounding and specialty pharmacy solutions.
China's compounding pharmacy market was valued at USD 340.1 million in 2025 and is expected to grow to USD 469.5 million by 2030.
China's compounding pharmacy market is projected to grow at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2030.
Key drivers include China's aging population, rising prevalence of chronic diseases, regulatory support for pharmaceutical customization, and increased healthcare provider and patient awareness of personalized medication solutions.
China's 6.7% CAGR exceeds the global compounding pharmacy market CAGR of 5.7%, indicating stronger regional growth momentum and market opportunity.
China is a leading market within Asia Pacific, with significant growth potential driven by healthcare infrastructure expansion and government initiatives supporting pharmaceutical innovation.
This study involved four major activities to estimate the current size of the compounding pharmacy market. We conducted exhaustive secondary research to gather information on the market, its peer markets, and its parent market. The team then validated these findings, assumptions, and sizing with industry experts across the value chain through primary research. We used both top-down and bottom-up approaches to estimate total market size. We then used data triangulation to estimate market size by segment and subsegment.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the compounding pharmacy market. The secondary sources used for this study include US Food and Drug Administration (FDA), American Pharmacists Association (APhA), International Academy of Compounding Pharmacists (IACP), National Community Pharmacists Association (NCPA), Parenteral Drug Association (PDA), American Society of Health-System Pharmacists (ASHP), Pharmacy Compounding Accreditation Board (PCAB), European Directorate for the Quality of Medicines & HealthCare (EDQM), European Medicines Agency (EMA), International Pharmaceutical Federation (FIP), Journal of Compounding & Specialty Pharmacy (JCSP), National Center for Biotechnology Information (NCBI), Pharmaceutical Research and Manufacturers of America (PhRMA), Pharma & Biopharma Outsourcing Association (PBOA), and World Journal of Pharmaceutical Research (WJPR). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis. These sources were also used to obtain key information on major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technology perspectives.
We conducted in-depth interviews with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. We interviewed primary sources from both the supply and demand sides of the market to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
We estimated the global size of the compounding pharmacy market using multiple approaches. We used a detailed market estimation approach to estimate and validate the market value and other dependent submarkets. We also used these methods extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.

After estimating the market size using the process described above, we divided the total market into several segments and subsegments. To complete the overall market analysis and obtain precise statistics for all segments and subsegments, we used data triangulation and market breakdown methods where applicable. We triangulated the data by examining factors and trends from both the demand and supply sides.
A compounding pharmacy is a specialized practice in which a licensed pharmacist combines, mixes, or alters raw drug ingredients to formulate customized medications tailored to individual patients' unique health needs. This process allows pharmacists to create pharmaceutical products in various forms, such as liquids, creams, gels, or capsules, and can be vital for patients with specific allergies, intolerances, or those needing dosages not commercially available. Compounding pharmacists often work closely with healthcare providers to develop formulas that address particular medical conditions, ensuring that each preparation is safe, effective, and personalized to optimize patient care. Additionally, compounding pharmacies adhere to stringent regulatory standards to maintain the integrity and quality of the medications they produce.
With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:
Full forecast, segment splits, and company analysis for all Compounding Pharmacy Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report